Carbapenem Antibiotic Therapy for VIM Carbapenemase-Producing Enterobacteriaceae Infections

University Hospital, Strasbourg, France70 enrolled

Overview

Carbapenemase-producing Enterobacteriaceae (CPE) infections are emerging infections that pose a therapeutic challenge. These infections mainly occur in patients with prolonged hospitalization and repeated exposure to antibiotics. Certain strains, notably VIM-producing strains, may remain sensitive to carbapenems. CPE VIM strains are rare in France, but represent the main CPE strains in many countries. They are historically the main type of carbapenemases isolated at the Strasbourg University Hospital.

The circulation of multi-antibiotic-resistant bacterial strains is significant at the Strasbourg University Hospital and the investigators wish to report their local experience in the use of carbapenems in infections with enterobacteria producing carbapenemase type VIM.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Carbapenemase-Producing Enterobacteriaceae

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patient (≥18) * Treated at the HUS for a VIM-producing enterobacteria infection between 01/01/2011 and 11/30/2022 * Subjects who have not expressed their opposition to the reuse of their data for scientific research purposes. Exclusion Criteria: * Patient having expressed his opposition to the retrospective reuse of his data for scientific research purposes.

Locations (1)

Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France

Strasbourg, France

RECRUITING

Outcomes

Primary Outcomes

Mortality at 28 days

Time frame: Mortality at 28 days after infection

Central Contacts

Baptiste HOELLINGER, MD

CONTACT

33 3 69 55 05 45 baptiste.hoellinger@chru-strasbourg.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.